Deborah Mukherji, Medical Oncologist at Clemenceau Medical Center, Dubai, shared on X:
“Best Poster Award – Advanced ProstateCa at ESMO26!
BioChiP phase II: Carboplatin 21.5% RR in pretreated mCRPC, higher RR in BRCA1/2-altered or RAD51-defined HRD tumours. Important implications for biomarker-guided use of affordable treatments in resource-limited settings.”
You can also read:
Phase III PEACE-1 at ESMO 2026: Long-Term Overall Survival With Abiraterone in De Novo mCSPC
